Table 1.
Baseline demographic, clinical characteristics according to cut-off value of fasting triglycerides in the study population
|
Variables |
Total |
Fasting triglycerides |
P-value |
|
|---|---|---|---|---|
| <1.2 mmol/L (N = 103) | ≥1.2 mmol/L (N = 226) | |||
| Demographics |
|
|
|
|
| Age, years |
59.3 ± 9.3 |
60.9 ± 9.6 |
58.7 ± 9.1 |
0.043 |
| Male gender |
241 (73.3) |
77 (74.8) |
164 (72.6) |
0.677 |
| Body mass index |
25.5 ± 3.0 |
24.9 ± 3.0 |
25.7 ± 3.0 |
0.045 |
| Risk factors |
|
|
|
|
| Current Smoking |
181 (55.0) |
59 (57.3) |
122 (54.0) |
0.577 |
| Hypertension |
221 (62.1) |
64 (62.1) |
157 (69.5) |
0.189 |
| Hyperlipidemia |
263 (79.9) |
76 (73.8) |
187 (82.7) |
0.060 |
| Peripheral vascular disease |
6 (1.8) |
2 (1.9) |
4 (1.8) |
0.914 |
| Prior Stroke |
13 (4.0) |
4 (3.9) |
9 (4.0) |
0.966 |
| Family history of CAD |
36 (10.9) |
10 (9.7) |
26 (11.5) |
0.628 |
| Angiographic findings |
|
|
|
0.481 |
| 1-vessel disease |
96 (29.2) |
30 (29.1) |
66 (29.2) |
|
| 2-vessel disease |
80 (24.3) |
21 (20.4) |
59 (26.1) |
|
| 3-vessel disease |
153 (46.5) |
52 (50.5) |
101 (44.7) |
|
| LVEF (%) |
62.0 ± 8.3 |
61.8 ± 8.8 |
62.1 ± 8.1 |
0.749 |
| Medical treatment |
|
|
|
|
| Aspirin |
321 (97.6) |
100 (97.1) |
221 (97.8) |
0.702 |
| Clopidogrel |
315 (95.7) |
100 (97.1) |
215 (95.1) |
0.415 |
| Beta-blocker |
271 (82.7) |
79 (76.7) |
193 (85.4) |
0.053 |
| ACE-I |
85 (25.8) |
29 (28.2) |
56 (24.8) |
0.516 |
| Statin |
320 (97.3) |
101 (98.1) |
219 (96.9) |
0.551 |
| DES implantation | 67 (20.4) | 22 (21.4) | 45 (19.9) | 0.762 |
CAD Coronary artery disease, LV-EF Left ventricular ejection fraction, ACE-I Angiotensin converting enzyme inhibitors, DES Drug eluting stent.